APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

593593 Disclosed are benzamide compounds with a substituted sulfonyl group on the amide and substituted heteroalkyl group at the 4 position of the benzamide. Examples of these compounds are: 4-[4-(3,3-diphenylprop-2-enyi)piperazin-1-yl]-N-[(3-nitrophenyl)sulfonyl]benzamide; N-[(2-bromophenyl)sulfony...

Full description

Saved in:
Bibliographic Details
Main Authors TAO, ZHI-FU, DING, HONG, ELMORE, STEVEN, W, SOUERS, ANDREW, J, KUNZER, AARON, R, WENDT, MICHAEL, D, SONG, XIAOHONG, HEXAMER, LAURA, SULLIVAN, GERARD, M
Format Patent
LanguageEnglish
Published 29.11.2013
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:593593 Disclosed are benzamide compounds with a substituted sulfonyl group on the amide and substituted heteroalkyl group at the 4 position of the benzamide. Examples of these compounds are: 4-[4-(3,3-diphenylprop-2-enyi)piperazin-1-yl]-N-[(3-nitrophenyl)sulfonyl]benzamide; N-[(2-bromophenyl)sulfonyl]-4-(4-{ [2-(4-chlorophenyl)cyclohex-1-en-1-yl]methyl} piperazin-1-yl)benzamide; N-[(3-bromophenyl)sulfonyl]-4-(4-{ [2-(4-chlorophenyl)cyclohex-1-en-1-yl]methyl} piperazin-1-yl)benzamide. The compounds inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. Also disclosed is a composition comprising one of the compounds and the use of one of the compounds for the manufacture of a medicament for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukaemia, colorectal cancer, oesophageal cancer, hepatocellular cancer, lymphoblastic leukaemia, follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, melanoma, myelogenous leukaemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or spleen cancer.
Bibliography:Application Number: NZ20100593593